Literature DB >> 12230916

Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells.

Constance Neely Wilson1, Vinod K Batra.   

Abstract

Previously, it was reported that A(1) adenosine receptor antagonists prevent endotoxin-induced acute lung injury and pulmonary arterial endothelial cell damage. In competition radioligand binding experiments in membranes prepared from human pulmonary artery endothelial cells (PAECs), lipopolysaccharides (LPSs) of Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa displaced the binding of a selective A(1) adenosine receptor antagonist [(125)I]-BWA844U (IC(50) values: 195 ng/ml, 290 ng/ml, 602 ng/ml, and 693 ng/ml, respectively) in a dose-dependent, competitive manner. There was no displacement of this radioligand by enterotoxin (< or = 10 microg/ml), diphosphoryl lipid A (< or = 10 microg/ml), and glycolipids, monosialoganglioside (< or = 1 microg/ml), lactocerebroside (< or = 100 microg/ml), or NBD galactocerebroside (< or = 100 microg/ml). Based on calculated IC(50) values, LPS (E. coli, IC(50) 111 ng/ml) displaced the selective A(1) adenosine receptor agonist, [(3)H]-2-chloro, N(6)-cyclopentyladenosine (CCPA) in human PAECs with a potency profile, CCPA > LPS > 2-phenylaminoadenosine (CV 1808), a selective A(2) adenosine receptor agonist. The potency profile for displacement of the selective A(2a) adenosine receptor agonist [(3)H]-CGS 21680 was CV 1808 > CCPA. LPS (E. coli 0.1 pg/ml-10 microg/ml) did not displace [(3)H]-CGS 21680 binding. In human PAECs, IL-6 and TXA(2) release induced by LPS (0-1 microg/ml) or CCPA (0-1 microM) at high doses was significantly reduced by the selective A(1) adenosine receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 1 microM). These data suggest that LPS binds to and activates A(1) adenosine receptors on human PAECs to induce the release of IL-6 and TXA(2). Activation of A(1) adenosine receptors on human PAECs by LPS, may contribute to the pathophysiology of acute lung injury associated with Gram-negative septicemia and endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230916     DOI: 10.1179/096805102125000470

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  16 in total

1.  E. coli lipopolysaccharide attenuates adenosine A(1) receptor-mediated increase in plasma exudation from the hamster cheek pouch.

Authors:  Xiao-pei Gao; Israel Rubinstein
Journal:  Inflamm Res       Date:  2010-10-06       Impact factor: 4.575

Review 2.  Adenosine receptors and angiogenesis.

Authors:  John A Auchampach
Journal:  Circ Res       Date:  2007-11-26       Impact factor: 17.367

Review 3.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

4.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 5.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Adenosine receptors regulate gap junction coupling of the human cerebral microvascular endothelial cells hCMEC/D3 by Ca2+ influx through cyclic nucleotide-gated channels.

Authors:  Almke Bader; Willem Bintig; Daniela Begandt; Anne Klett; Ina G Siller; Carola Gregor; Frank Schaarschmidt; Babette Weksler; Ignacio Romero; Pierre-Olivier Couraud; Stefan W Hell; Anaclet Ngezahayo
Journal:  J Physiol       Date:  2017-02-14       Impact factor: 5.182

7.  Extracellular adenosine-induced Rac1 activation in pulmonary endothelium: Molecular mechanisms and barrier-protective role.

Authors:  Anita Kovacs-Kasa; Kyung Mi Kim; Mary Cherian-Shaw; Stephen M Black; David J Fulton; Alexander D Verin
Journal:  J Cell Physiol       Date:  2018-03-07       Impact factor: 6.384

8.  Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation.

Authors:  Ahmed Nadeem; Peter C M Obiefuna; Constance N Wilson; S Jamal Mustafa
Journal:  Eur J Pharmacol       Date:  2006-09-08       Impact factor: 4.432

9.  A novel post-exposure medical countermeasure L-97-1 improves survival and acute lung injury following intratracheal infection with Yersinia pestis.

Authors:  Constance N Wilson; Constance O Vance; Timothy M Doyle; David S Brink; George M Matuschak; Andrew J Lechner
Journal:  Innate Immun       Date:  2011-08-23       Impact factor: 2.680

Review 10.  Adenosine receptors and asthma in humans.

Authors:  C N Wilson
Journal:  Br J Pharmacol       Date:  2008-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.